[go: up one dir, main page]

MX2022005083A - Formulaciones en polvo seco de anticuerpos de unión a linfopoyetina estromal tímica (tslp) y métodos para usarlos. - Google Patents

Formulaciones en polvo seco de anticuerpos de unión a linfopoyetina estromal tímica (tslp) y métodos para usarlos.

Info

Publication number
MX2022005083A
MX2022005083A MX2022005083A MX2022005083A MX2022005083A MX 2022005083 A MX2022005083 A MX 2022005083A MX 2022005083 A MX2022005083 A MX 2022005083A MX 2022005083 A MX2022005083 A MX 2022005083A MX 2022005083 A MX2022005083 A MX 2022005083A
Authority
MX
Mexico
Prior art keywords
dry powder
tslp
powder formulations
methods
thymic stromal
Prior art date
Application number
MX2022005083A
Other languages
English (en)
Inventor
David Lechuga-Ballesteros
Emma Suzanne Cohen
Catherine Eugenie Chaillan Huntington
Susan Hoe
Prakash Manikwar
Saba Ghazvini
Kellisa Beth Hansen
Dexter Joseph D''sa
Roland Wilhelm Kolbeck
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MX2022005083A publication Critical patent/MX2022005083A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Professional, Industrial, Or Sporting Protective Garments (AREA)

Abstract

La tecnología de la presente se relaciona, en general, con formulaciones en polvo seco de anticuerpos específicos para la linfopoyetina estromal tímica (TSLP), así como también métodos para tratar asma, con el uso de formulaciones en polvo seco, convenientemente vía administración pulmonar.
MX2022005083A 2019-10-28 2020-10-27 Formulaciones en polvo seco de anticuerpos de unión a linfopoyetina estromal tímica (tslp) y métodos para usarlos. MX2022005083A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962926833P 2019-10-28 2019-10-28
PCT/EP2020/080201 WO2021083908A1 (en) 2019-10-28 2020-10-27 Dry powder formulations of thymic stromal lymphopoietin (tslp)-binding antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2022005083A true MX2022005083A (es) 2022-07-19

Family

ID=73030137

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005083A MX2022005083A (es) 2019-10-28 2020-10-27 Formulaciones en polvo seco de anticuerpos de unión a linfopoyetina estromal tímica (tslp) y métodos para usarlos.

Country Status (31)

Country Link
US (3) US11904053B2 (es)
EP (2) EP4534075A3 (es)
JP (3) JP7680654B2 (es)
KR (1) KR20220088752A (es)
CN (1) CN114867748B (es)
AR (1) AR120309A1 (es)
AU (1) AU2020376222A1 (es)
CA (1) CA3154999A1 (es)
CL (1) CL2023003432A1 (es)
CO (1) CO2022005391A2 (es)
CR (1) CR20220189A (es)
DK (1) DK4051708T3 (es)
ES (1) ES3017790T3 (es)
FI (1) FI4051708T3 (es)
HR (1) HRP20250300T1 (es)
HU (1) HUE071069T2 (es)
IL (1) IL292437A (es)
LT (1) LT4051708T (es)
MA (1) MA57519B1 (es)
MX (1) MX2022005083A (es)
MY (1) MY210226A (es)
PH (1) PH12022551022A1 (es)
PL (1) PL4051708T3 (es)
PT (1) PT4051708T (es)
RS (1) RS66646B1 (es)
SI (1) SI4051708T1 (es)
SM (1) SMT202500220T1 (es)
TW (1) TWI891670B (es)
UA (1) UA129038C2 (es)
WO (1) WO2021083908A1 (es)
ZA (1) ZA202205936B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024516962A (ja) * 2021-04-19 2024-04-18 メドイミューン・リミテッド 安定性が改善された抗ＴＳＬＰ Ｆａｂ
US20230270668A1 (en) * 2021-10-11 2023-08-31 Augmenta Bioworks, Inc. Dry formulations of anti-sars-cov-2 virus antibodies and compositions and methods of use thereof
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
WO2025049345A1 (en) 2023-08-25 2025-03-06 Proteologix Us Inc. Anti-il-13 multispecific antibody constructs and uses thereof
WO2025163008A1 (en) 2024-01-29 2025-08-07 Astrazeneca Ab Compositions of thymic stromal lymphopoietin (tslp) binding fragments and methods of use thereof
WO2025242605A1 (en) 2024-05-20 2025-11-27 Medimmune Limited Inhaler and capsule for delivering thymic stromal lymphopoietin (tslp)-binding antibodies

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4970154A (en) 1987-10-09 1990-11-13 Baylor College Of Medicine Method for inserting foreign genes into cells using pulsed radiofrequency
US5106627A (en) 1987-11-17 1992-04-21 Brown University Research Foundation Neurological therapy devices
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
DK0463151T3 (da) 1990-01-12 1996-07-01 Cell Genesys Inc Frembringelse af xenogene antistoffer
US5521288A (en) 1990-03-26 1996-05-28 Bristol-Myers Squibb Company CD28IG fusion protein
JP2938569B2 (ja) 1990-08-29 1999-08-23 ジェンファーム インターナショナル，インコーポレイティド 異種免疫グロブリンを作る方法及びトランスジェニックマウス
EP0652950B1 (en) 1992-07-24 2007-12-19 Amgen Fremont Inc. Generation of xenogeneic antibodies
ES2178654T3 (es) 1993-08-12 2003-01-01 Neurotech Sa Capsulas biocompatibles inmonoaisladoras que contienen celulas geneticamente alteradas para el suministro de moleculas biologicamente activas.
US5484720A (en) 1994-09-08 1996-01-16 Genentech, Inc. Methods for calcium phosphate transfection
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
US5679559A (en) 1996-07-03 1997-10-21 University Of Utah Research Foundation Cationic polymer and lipoprotein-containing system for gene delivery
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
AU752433B2 (en) 1997-09-23 2002-09-19 Bundesrepublik Deutschland letzvertreten durch Den Direktor des Robert-Koch-Instituts Costimulating T-cell polypeptide, monoclonal antibodies, their preparation and use
DE19821060A1 (de) 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
US7708993B2 (en) 1999-02-03 2010-05-04 Amgen Inc. Polypeptides involved in immune response
EP2332978B1 (en) 1999-02-03 2014-04-02 Amgen, Inc Novel polypeptides involved in immune response
US7435796B1 (en) 1999-02-03 2008-10-14 Amgen Inc. Antibodies which bind B7RP1
DK1218504T3 (da) 1999-09-21 2007-11-12 Genetics Inst Llc GL50 molekyler og anvendelser deraf
DK1223915T3 (da) * 1999-10-29 2006-03-06 Nektar Therapeutics Törpulverpræparater med forbedret dispersivitet
AU2005254062B2 (en) 2002-04-11 2011-02-17 Medimmune, Llc High pressure spray-dry of bioactive materials
PL1915398T3 (pl) 2005-07-18 2016-10-31 Ludzkie przeciwciała neutralizujące anty-B7RP1
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
JP2010530233A (ja) 2007-06-20 2010-09-09 アイアールエム・リミテッド・ライアビリティ・カンパニー アレルギー疾患を処置する方法および組成物
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
UY32038A (es) 2008-08-08 2010-03-26 Glaxo Wellcome Mfg Pte Ltd Inmunoblobulinas anti-cd127 y sus usos
BR112012010707B1 (pt) 2009-11-04 2022-08-30 Merck Sharp & Dohme Corp Anticorpo ou fragmento de ligação ao antígeno do mesmo, composição, e, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo
WO2012007495A1 (en) 2010-07-15 2012-01-19 F. Hoffmann-La Roche Ag Antibodies specifically binding to human tslpr and methods of use
US20140227250A1 (en) 2012-08-23 2014-08-14 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
WO2016142426A1 (en) * 2015-03-11 2016-09-15 Glaxosmithkline Intellectual Property Development Limited Tslp binding proteins
MY186352A (en) 2015-09-09 2021-07-15 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
AU2016320743B2 (en) * 2015-09-09 2019-07-04 Novartis Ag Targeted delivery of spray-dried formulations to the lungs
MX2018003038A (es) 2015-09-09 2018-04-11 Novartis Ag Moleculas de union a linfopoyetina estromal timica (tslp) y metodos de uso de las moleculas.
CL2016000915A1 (es) 2016-04-15 2016-11-11 Univ Pontificia Catolica Chile Uso de una composición que comprende al menos un anticuerpo monoclonal humanizado o moléculas neutralizantes que neutralizan la función de las moléculas tslp y/o tslpr y/o ox40l y/o cd177, para preparar un medicamento para el tratamiento o para aminorar los síntomas y enfermedad de pacientes infectados con el metapneumovirus humano (hmpv)
JOP20190243A1 (ar) 2017-04-12 2019-10-13 Medimmune Llc علاج الربو بجسم مضاد لـ tslp
MX2020007745A (es) 2018-01-26 2020-09-25 Novartis Ag Administracion de dosis elevadas de terapias inhaladas.
JP2024516962A (ja) * 2021-04-19 2024-04-18 メドイミューン・リミテッド 安定性が改善された抗ＴＳＬＰ Ｆａｂ

Also Published As

Publication number Publication date
US20250099386A1 (en) 2025-03-27
HUE071069T2 (hu) 2025-07-28
BR112022008031A2 (pt) 2022-07-12
CN114867748B (zh) 2025-12-30
CA3154999A1 (en) 2021-05-06
CN114867748A (zh) 2022-08-05
PL4051708T3 (pl) 2025-04-28
WO2021083908A1 (en) 2021-05-06
UA129038C2 (uk) 2024-12-25
US20210121406A1 (en) 2021-04-29
EP4051708B1 (en) 2025-01-08
US20230201120A1 (en) 2023-06-29
JP2025169423A (ja) 2025-11-12
TW202131947A (zh) 2021-09-01
AU2020376222A1 (en) 2022-06-02
SI4051708T1 (sl) 2025-06-30
US11904053B2 (en) 2024-02-20
EP4051708A1 (en) 2022-09-07
AR120309A1 (es) 2022-02-09
US12178911B2 (en) 2024-12-31
EP4534075A2 (en) 2025-04-09
PH12022551022A1 (en) 2023-03-06
PT4051708T (pt) 2025-04-03
EP4534075A3 (en) 2025-12-17
MY210226A (en) 2025-09-04
DK4051708T3 (da) 2025-03-24
RS66646B1 (sr) 2025-04-30
JP2022554249A (ja) 2022-12-28
CL2023003432A1 (es) 2024-05-17
MA57519B1 (fr) 2025-04-30
SMT202500220T1 (it) 2025-07-22
JP7680654B2 (ja) 2025-05-21
ZA202205936B (en) 2025-11-26
FI4051708T3 (fi) 2025-03-31
ES3017790T3 (en) 2025-05-13
KR20220088752A (ko) 2022-06-28
TWI891670B (zh) 2025-08-01
LT4051708T (lt) 2025-04-10
HRP20250300T1 (hr) 2025-04-25
CO2022005391A2 (es) 2022-08-19
IL292437A (en) 2022-06-01
CR20220189A (es) 2022-08-19
JP2025094236A (ja) 2025-06-24

Similar Documents

Publication Publication Date Title
MX2022005083A (es) Formulaciones en polvo seco de anticuerpos de unión a linfopoyetina estromal tímica (tslp) y métodos para usarlos.
CO2019011462A2 (es) Tratamiento para el asma con anticuerpo anti-tslp
MX2020006689A (es) Composiciones de vcar y metodos de uso.
CO2018002446A2 (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
ECSP18023386A (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
BR112017014230A2 (pt) endófitos de semente através de cultivares e espécies, composições associadas e métodos de uso dos mesmos
DOP2018000272A (es) Conjugados de anticuerpo anti-egfr y fármaco
MX2019008872A (es) Prevencion y tratamiento de da?o o enfermedad osea y cartilago.
CY1116365T1 (el) Στρωματικα βλαστικα κυτταρα
AR095348A1 (es) Medios de cultivo celular y métodos de producción de anticuerpos
Wang et al. The Early Cretaceous non-Cypridea Ostracoda from Yixian and Jiufotang formations of western Liaoning (China)
MX2021005956A (es) Composiciones biologicas secas y metodos de las mismas.
DOP2016000220A (es) PROTEÍNAS DE FUSIÓN TATk-CDKL5, COMPOSICIONES, FORMULACIONES Y USO DE ESTAS.
CL2020002301A1 (es) Suplemento de cutícula para producción vegetal
BR112016024635A2 (pt) meios de crescimento microbiológico e métodos de uso do mesmo
MX2021008983A (es) Atributos de aflibercept y metodos de caracterizacion y modificacion de los mismos.
CO2017007338A2 (es) Composición que comprende dos cepas de las especies microbianas lactobacillus rhamnosus y bifidobacterium longum capaces de incrementar la fertilidad masculina
BR112017014792A2 (pt) material em folha fumável, método de preparação de uma folha de material fumável, artigo de fumar e uso de um material em folha fumável
CO2023010900A2 (es) Anticuerpos anti- pdgf-b y métodos de su uso para tratar la hipertensión arterial pulmonar (pah)
MX2019013570A (es) Particulas portadoras novedosas para formulaciones de polvo seco para inhalacion.
CL2019000416A1 (es) Formulaciones de azadiractina estables en almacenamiento y métodos para su preparación y utilización.
CL2019003911A1 (es) Vacuna antitumoral que comprende cuerpos celulares, atp y polimixina b; y uso combinado de cuerpos celulares, atp y polimixina b para potenciar la respuesta antitumoral activando células dendríticas.
Zhang et al. Showcasing research from School of Life Science, University of Science and Technology of China, No. 443, Huangshan Road ShuShan District, Hefei, Anhui, 230027, PR China.